XORTX Other Current Assets from 2010 to 2024

XRTX Stock  USD 1.19  0.03  2.59%   
XORTX Therapeutics Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets are likely to outpace its year average in 2024. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2010-12-31
Previous Quarter
560.4 K
Current Value
701 K
Quarterly Volatility
333.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of XORTX Therapeutics over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. XORTX Therapeutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Pretty Stable
   Other Current Assets   
       Timeline  

XORTX Other Current Assets Regression Statistics

Arithmetic Mean764,910
Geometric Mean720,646
Coefficient Of Variation43.60
Mean Deviation180,969
Median689,373
Standard Deviation333,477
Sample Variance111.2B
Range1.5M
R-Value0.13
Mean Square Error117.8B
R-Squared0.02
Significance0.65
Slope9,644
Total Sum of Squares1.6T

XORTX Other Current Assets History

2024701 K
2023560.4 K
2022379.6 K
2021M
20201.9 M
2019741.2 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets560.4 K701 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.